Skip to main content
. 2020 Apr 11;9(4):944. doi: 10.3390/cells9040944

Figure 2.

Figure 2

Endocytic activity of MAP1889c-treated dendritic cells (DCs): Bone marrow-derived dendritic cells (BMDCs) were treated with 100 ng/mL Lipopolysaccharide (LPS) or 1 or 10 μg/mL MAP1889c for 24 h, incubated with dextran- fluorescein isothiocyanate (FITC) at 37 °C or 4 °C for 1 h, and then stained with a phycoerythrin (PE)-conjugated anti-CD11c+ antibody. Endocytic activity was assessed by flow cytometric analysis of dextran-FITC uptake. The percentage of CD11c+dextran+ cells is indicated. The bar graphs depict the mean values ± SD (n = 3). * p < 0.05 and *** p < 0.001 for treatment compared with the untreated controls (CON) or for the difference between treatment data. n.s., no significant difference.